Molecular science
Gene and RNA research, nucleic acid chemistry and delivery design.
About us
From scientific insight
to human possibility.
Scientists, clinicians and collaborators united by a shared ambition: helping genetic medicines reach the tissues that need them.
Explore about us01 / The beginning
A scientific challenge.
A very human reason.
Every possibility begins with a person.
Founded in the UK · 2019
Bringing delivery science closer to patient need.
Dawn brings together scientists, clinicians and entrepreneurs to tackle a central challenge in genetic medicine: getting therapeutic instructions to the tissues that need them.
Our lead focus is Hurler syndrome. Our broader ambition is to build delivery technologies that support new approaches to rare genetic, neurological and musculoskeletal diseases.
The disease behind our lead programme02 / Connected expertise
Progress needs more than one perspective.
Clinical understanding
Experience of disease, patient needs and translational research.
Development expertise
Manufacturing, safety studies and regulatory planning.
03 / Our delivery approach
Two complementary platforms.
One delivery ambition.
sLV
Stealth lentiviral vectors
A modified viral carrier designed to deliver a functional gene in vivo.
Explore the science
iLNP
Targeted lipid nanoparticles
Lipid-based carriers engineered for tissue targeting and flexible genetic payloads.
Explore the science04 / How we work
Principles that guide the next decision.
Evidence first
We use milestone-based work packages and formal Go/No-Go decision points to keep development focused, measurable, and capital efficient.
05 / A focused path forward
Build the evidence. Earn the next step.
- 01
Establish the signal
Generate and examine preclinical evidence for DAWN-01.
- 02
Strengthen the programme
Develop manufacturing, dose strategy and safety workstreams.
- 03
Prepare the next stage
Align the evidence package and regulatory plan before clinical development.
06 / The people behind Dawn
Meet the Geniuses
behind Dawn.
Founder & Chief Executive Officer
Professor Nagy Habib
A career connecting surgery, scientific research and therapeutic innovation informs Dawn’s approach to translating new ideas into development programmes.
Meet the scientific teamBuild a partnership with DawnClear answers
Questions, answered.
What does Dawn Therapeutics do?
Dawn Therapeutics is a UK preclinical biotechnology company developing delivery platforms for genetic medicines. Its lead programme is DAWN-01 for Hurler syndrome.
Discover more